For instance, Jain et al. demonstrated that the combination of HER2 inhibitors (trastuzumab or lapatinib) with an anti-VEGFR2 antibody (bevacizumab) significantly slowed tumor growth and improved survival in patients with HER2-amplified breast cancer brain metastases [53]. This evidence concerns the gene KDR and neoplasm.